Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 deucravacitinib study in adults with active Sjögren’s syndrome
NL-OMON59737Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI at Week 52. Started Sep 2024; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON59737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59737.